Theresa LaVallee

Theresa LaVallee, Ph.D. is the Chief Development Officer at Coherus BioSciences, a position she has held since December 2021.14 She brings over 25 years of experience in drug discovery and development, with a particular focus on oncology and immunotherapy.12

Career Highlights

Dr. LaVallee's professional journey includes several notable positions:

• Vice President of Translational Medicine and Regulatory Affairs at the Parker Institute for Cancer Immunotherapy (June 2017 - December 2021)4
• Senior Vice President roles at Celldex Therapeutics and Kolltan Pharmaceuticals4
• Senior Director at MedImmune (AstraZeneca) from 2008 to 2013, where she worked on developing checkpoint inhibitors and related diagnostics14
• Senior Director at EntreMed for a decade (1998-2008)4

Education and Expertise

Dr. LaVallee earned her Ph.D. from the University of California, Los Angeles (UCLA) and her bachelor's degree from the University of California, Santa Barbara.12 Her expertise spans:

• Immuno-oncology
• Translational medicine
• Regulatory affairs
• Drug discovery and development
• Clinical strategy

Recognition

In 2021, Dr. LaVallee was highlighted by IO360 in the Woman Leadership in Immuno-oncology Newsletter, and in 2023, she was named one of The Top 25 Woman Leaders in Biotechnology.2

Role at Coherus BioSciences

As Chief Development Officer, Dr. LaVallee oversees all regulatory matters and product development functions at Coherus BioSciences.3 She plays a crucial role in advancing the company's immuno-oncology pipeline, particularly focusing on combinations with toripalimab, their PD-1 inhibitor.3

Theresa LaVallee is recognized for her scientific acumen, strong communication skills, and leadership abilities in the biopharmaceutical industry.4